Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of E7389 in Patients With Solid Tumors
jRCT2080221233Phase 1
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin in Nonhematologic neoplasms, sponsored by Eisai Co., Ltd.
02
Drugs
eribulin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221233.